These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2503723)

  • 21. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of continuous treatment of stallions with high levels of a potent GnRH analogue.
    Boyle MS; Skidmore J; Zhang J; Cox JE
    J Reprod Fertil Suppl; 1991; 44():169-82. PubMed ID: 1795259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
    Labrie F; Dupont A; Belanger A; Lacoursiere Y; Raynaud JP; Husson JM; Gareau J; Fazekas AT; Sandow J; Monfette G
    Prostate; 1983; 4(6):579-94. PubMed ID: 6415630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
    Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
    J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
    Moguilewsky M; Tournemine C
    Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total androgen blockade for metastatic cancer of the prostate.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
    Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.